| Literature DB >> 35027800 |
Deependra K Rai1, Nishant Sahay2, Pallavi Lohani3.
Abstract
OBJECTIVES OF THE STUDY: The objectives of the study were to assess the mortality among critically ill coronavirus disease (COVID) patients and to look at the factors which could have a bearing on mortality of these patients presenting to our designated tertiary COVID care institute.Entities:
Keywords: Coronavirus disease-2019; Intensive care unit; Mortality; Predictors
Year: 2021 PMID: 35027800 PMCID: PMC8693122 DOI: 10.5005/jp-journals-10071-24048
Source DB: PubMed Journal: Indian J Crit Care Med ISSN: 0972-5229
Flowchart 1Flow diagram of study patients
Clinicodemographic characteristics of COVID patients admitted to ICU
|
|
|
|
|
|
|---|---|---|---|---|
| Age | 57.63 ± 14.14 | 60.01 ± 14.28 | 49.73 ± 14.14 | |
| <20 | 01 | 00 | 01 (100) | <0.00 |
| 21–30 | 09 | 04 (44.44) | 5 (55.56) | |
| 31–40 | 27 | 15 (55.56) | 12 (44.44) | |
| 41–50 | 48 | 33 (68.75) | 15 (31.25) | |
| 51–60 | 77 | 56 (72.73) | 21 (27.27) | |
| >60 | 131 | 117 (89.31) | 14 (10.69) | |
| Gender | 0.979 | |||
| Male | 233 | 179 (79.55) | 54 (79.41) | |
| Female | 60 | 46 (20.44) | 14 (20.59) | |
| Comorbidities | ||||
| At least one comorbidity (+) | 206 (70.30) | 170 (75.55) | 36 (44.11) | |
| Diabetes | 129 | 109 (84.50) | 20 (15.50) | 0.006 |
| HTn | 129 | 112 (86.82) | 17 (13.18) | <0.00 |
| CKD | 29 | 28 (96.55) | 01 (3.45) | 0.005 |
| CAD | 25 | 20 (80.00) | 05 (20.00) | 0.691 |
| COPD/asthma | 16 | 15 (93.75) | 01 (6.25) | 0.130 |
| Hypothyroidism | 29 | 23 (79.31) | 06 (20.69) | 0.735 |
| Malignancy | 07 | 06 (85.71) | 01 (14.29) | 0.571 |
| Duration in ICU (days) | 6.32 ± 4.95 | 5.84 ± 4.0 | 7.89 ± 5.56 | 0.0003 |
| <1 day | 05 | 01 (0.4) | 04 (5.88) | |
| 1–5 | 148 | 123 (54.66) | 25 (36.76) | |
| 6–10 | 93 | 76 (33.77) | 17 (25) | |
| 11–15 | 34 | 18 (8) | 16 (23.52) | |
| 16–20 | 09 | 03 (1.33) | 06 (8.82) | |
| >20 days | 04 | 03 (1.33) | 01 (1.47) |
CKD, chronic kidney disease; CAD, coronary artery disease; ICU, intensive care unit
Laboratory results on admission
|
|
|
|
| |
|---|---|---|---|---|
| Hemoglobin | 11.49 ± 5.06 | 10.95 ± 2.22 | 12.08 ± 1.50 | 0.0001 |
| TLC | 12.83 ± 7.68 | 14.11 ± 8.13 | 8.65 ± 3.59 | <0.00 |
| Platelet count | 210.66 ± 111.36 | 208.97 ± 115.39 | 216.26 ± 97.44 | 0.6369 |
| Neutrophil | 83.40 ± 14.99 | 85.52 ± 14.53 | 76.43 ± 14.46 | <0.00 |
| Lymphocyte | 12.27 ± 12.12 | 10.35 ± 11.76 | 18.63 ± 11.19 | <0.00 |
| NLR >3.3 | 251 (85.67) | 203 (80.88) | 48 (19.12) | <0.00 |
| Eosinophil | 0.41 ± 0.90 | 0.29 ± 0.72 | 0.80 ± 1.26 | <0.00 |
| SGOT | 103.08 ± 281.54 | 113.49 ± 313.53 | 68.80 ± 53.74 | 0.2524 |
| SGPT | 89.44 ± 110.225 | 91.43 ± 119.02 | 83.34 ± 74.13 | 0.5968 |
| Total bilirubin | 1.88 ± 1.17 | 1.27 ± 1.31 | 0.19 ± 0.36 | 0.0268 |
| Direct bilirubin | 0.45 ± 0.57 | 0.50 ± 0.64 | 0.32 ± 0.11 | 0.0235 |
| Alk. phos. | 120.79 ± 92.11 | 128.46 ± 100.41 | 94.23 ± 54.79 | 0.0069 |
| Total protein | 6.49 ± 1.03 | 6.35 ± 1.07 | 7.04 ± 0.66 | <0.00 |
| S. albumin | 3.28 ± 0.57 | 3.15± 0.55 | 3.73 ± 0.41 | <0.00 |
| Globulin | 3.22 ± 0.57 | 3.19 ± 0.6 | 3.30 ± 0.47 | 0.1779 |
| Blood urea | 75.95 ± 73.95 | 80.05 ± 78.27 | 35.91 ± 35.12 | <0.00 |
| Creatinine | 1.65 ± 2.02 | 1.89 ± 2.25 | 0.85 ± 0.49 | <0.00 |
| Sodium | 139.22 ± 73.45 | 141.58 ± 83.73 | 134.39 ± 5.60 | 0.4802 |
| Potassium | 4.46 ± 0.86 | 4.49 ± 0.89 | 4.35 ± 0.71 | 0.2402 |
| Calcium | 8.32 ± 0.97 | 8.19 ± 1.03 | 8.77 ± 0.52 | 0.002 |
| CRP | 132.13 ± 119.0 ( | 145.83 ± 132.21 ( | 62.52 ± 65.87 ( | 0.0008 |
| Ferritin | 963.47 ± 980.06 ( | 1061.86 ± 1128.57 ( | 569.92 ± 440.84 ( | 0.0068 |
| LDH | 1240.55 ± 812.86 ( | 1336.10 ± 771.24 ( | 808.79 ± 285.69 ( | 0.0006 |
| D-dimer | 4.06 ± 10.63 ( | 5.33 ± 13.63 ( | 1.91 ± 3.97 ( | 0.0844 |
| PT | 14.97 ± 8.16 ( | 15.16 ± 7.82 ( | 14.15 ± 8.73 ( | 0.451 |
| INR | 1.21 ± 1.05 ( | 1.23 ± 1.11 ( | 1.10 ± 0.77 ( | 0.432 |
CRP, C-reactive protein; PT, prothrombin time; INR, international normalized ratio
Hazard ratio for the fatal outcomes among COVID-19 ICU patients (N = 213) (p <0.00)
|
|
|
|---|---|
| Age | 1.01 (0.998–1.025), 0.086 |
| Comorbidities | |
| Asthma | 1.73 (0.952–3.129), 0.072 |
| One or more comorbidities | 1.16 (0.794–1.694), 0.443 |
| Inflammatory markers | |
| Neutrophilia (neutrophils >80%) | 2.19 (1.287–3.740), 0.002 |
| Lymphopenia (lymphocytes <20%) | 0.89 (0.418–1.916), 0.776 |
| D-dimer >1.00 | 2.00 (1.385–2.891), <0.000 |
| Treatment outcomes | |
| Duration in ICU (7–14 days) | 2.05 (1.219–3.452), 0.007 |
| Duration on mechanical ventilation (>7 days) | 1.18 (1.059–1.299), 0.001 |
Multivariable Cox proportional hazard model was formulated to predict the risk of death among COVID-19 patients admitted to ICU. The model is highly significant (χ2 = 60.16, df = 08, p <0.000)
Figs 1A to FKaplan–Meier curve showing differences in survival probabilities of COVID-19 patients on the basis of distribution of age and blood parameters
Figs 2A to DKaplan–Meier curve showing differences in survival probabilities in COVID-19 patients with comorbidity (DM, diabetes mellitus; HTn, hypertension)